AtriCure (NASDAQ:ATRC) vs. Hero Technologies (OTCMKTS:HENC) Head-To-Head Analysis

Hero Technologies (OTCMKTS:HENC) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Volatility and Risk

Hero Technologies has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Hero Technologies and AtriCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hero Technologies	0	0	0	0	0.00
AtriCure	1	0	10	0	2.82

AtriCure has a consensus price target of $52.44, indicating a potential upside of 29.75%. Given AtriCure’s stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Hero Technologies.

Insider and Institutional Ownership

99.1% of AtriCure shares are held by institutional investors. 0.2% of Hero Technologies shares are held by insiders. Comparatively, 3.5% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Hero Technologies and AtriCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hero Technologies	N/A	N/A	N/A
AtriCure	-5.55%	-2.54%	-1.93%

Valuation & Earnings

This table compares Hero Technologies and AtriCure”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hero Technologies	N/A	N/A	-$540,000.00	N/A	N/A
AtriCure	$518.31 million	3.88	-$44.70 million	($0.61)	-66.26

Hero Technologies has higher earnings, but lower revenue than AtriCure.

Summary

AtriCure beats Hero Technologies on 7 of the 11 factors compared between the two stocks.

About Hero Technologies

Hero Technologies Inc. operates as an early-stage cannabis company. It focuses on the provision of BlackBox, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and the cultivation of large flowering plants and create increased harvest efficiencies. The company also intends to offer cannabis genetic engineering farmland for medical and recreational cannabis cultivation, production, distribution, packaging, and retail operations, as well as for dispensaries. The company is based in Dover, Delaware.

About AtriCure

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.